The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review

Author(s): Sepideh Mansouri , Parisa Mokhtari-Hesari , Fatemeh Naghavi-al-Hosseini , Keivan Majidzadeh-A , Leila Farahmand* .

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 6 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Numerous studies have defined the outstanding role of circulating tumor cells (CTC) in the management of cancer, particularly the ones in association with primary tumor metastases.

Objective: The overall aim of the present study was to investigate whether CTCs may serve as a clinical prognostic marker for survival in primary breast cancer.

Methods: Articles Published from June 2011 to July 2017 in PubMed, EMBase, and Cochrane library databases were thoroughly screened for selecting the ones meeting the inclusion criteria.

Result: Studies applying CellSearch® method demonstrated the risk ratios (RR) of 2.51 (95% CI: 1.78- 3.54), 3.98 (95% CI: 2.28- 6.95), 5.59 (95% CI: 3.29- 9.51), and 3.38 (95% CI: 1.88- 6.06) for death rate and relapse rates of 2.48 (95% CI: 1.89 - 3.26), 3.62 (95% CI: 2.37 - 5.51), 4.45 (95% CI: 2.94 - 6.73), and 2.88 (95 % CI: 1.99 - 4.17) at four CTC positive cut points (≥ 1, ≥ 2, ≥ 3, and ≥ 5 CTCs/7.5 ml). Two studies applying the AdnaTest® also documented increased death (RR: 1.38, 95 % CI: 0.42- 4.49) and relapse rates (RR: 2.97, 95 % CI: 1.23 - 7.18)).

Conclusion: Results of this meta-analysis allude CTCs as potent prognostic markers in primary breast cancers prior to any systemic therapy especially when it is studied via CellSearch® administration, considering that the more the CTCs, the greater the death and relapse rates.

Keywords: Breast cancer, CTC, death rate, primary, prognosis, relapse rate.

[1]
Ursaru M, Jari I, Naum A, Scripcariu V, Negru D. Causes Of Death In Patients With Stage 0-II Breast Cancer. Rev Med Chir Soc Med Nat Iasi 2015; 119(2): 374-8.
[2]
Balic M, Williams A, Dandachi N, Cote RJ. Micrometastasis: Detection methods and clinical importance. Cancer Biomark 2010; 9(1-6): 397-419.
[3]
Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353(8): 793-802.
[4]
Kanwar N, Done SJ. Molecular profiling and significance of circulating tumor cell based genetic signatures. Adv Exp Med Biol 2017; 994: 143-67.
[5]
Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells: Clinical validity and utility. Int J Clin Oncol 2017; 22(3): 421-30.
[6]
Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 1999; 5(8): 1950-60.
[7]
Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther 2014; 142(3): 271-80.
[8]
Dementeva N, Kokova D, Mayboroda OA. Current methods of the Circulating Tumor Cells (CTC) analysis: A brief overview. Curr Pharm Des 2017; 23(32): 4726-8.
[9]
Gwak H, Kim J, Kashefi-Kheyrabadi L, Kwak B, Hyun KA, Jung HI. Progress in circulating tumor cell research using microfluidic devices. Micromachines 2018; 9(7): E353.
[10]
Riethdorf S, O’Flaherty L, Hille C, Pantel K. Clinical applications of the CellSearch platform in cancer patients. Adv Drug Deliv Rev 2018; 125: 102-21.
[11]
Van der Auwera I, Peeters D, Benoy IH, et al. Circulating tumour cell detection: A direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer. Br J Cancer 2010; 102(2): 276-84.
[12]
Zhang Y, Lv Y, Niu Y, Su H, Feng A. Role of Circulating Tumor Cell (CTC) monitoring in evaluating prognosis of triple-negative breast cancer patients in China. Med Sci Monit 2017; 23: 3071-9.
[13]
Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol 2014; 15(4): 406-14.
[14]
Kundu MG, Acharyya S. Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studies. Contemp Clin Trials 2017; 53: 20-8.
[15]
Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; 18(20): 5701-10.
[16]
Khatami F, Aghayan HR, Sanaei M, Heshmat R, Tavangar SM, Larijani B. The potential of circulating tumor cells in personalized management of breast cancer: A systematic review. Acta Medica Iranica 2017; 55(3): 175-93.
[17]
Liao Y, Wang SY, Meng XY, et al. Circulating tumor cells in breast cancer and its association with tumor clinicopathological characteristics: A meta-analysis. Med Oncol 2014; 31(12): 343.
[18]
Berghuis AM, Koffijberg H, Prakash J, Terstappen LW, Ijzerman MJ. Detecting blood-based biomarkers in metastatic breast cancer: A systematic review of their current status and clinical utility. Int J Mol Sci 2017; 18(2): E363.
[19]
Lv Q, Gong L, Zhang T, et al. Prognostic value of circulating tumor cells in metastatic breast cancer: A systemic review and meta-analysis. Clin Transl Oncol 2016; 18(3): 322-30.
[20]
Zhao S, Liu Y, Zhang Q, et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: A meta-analysis of published literature. Breast Cancer Res Treat 2011; 130(3): 809-16.
[21]
Lu YJ, Wang P, Wang X, Peng J, Zhu YW, Shen N. The significant prognostic value of circulating tumor cells in triple-negative breast cancer: A meta-analysis. Oncotarget 2016; 7(24): 37361-9.
[22]
Fei F, Du Y, Di G, Wu J, Shao Z. Are changes in circulating tumor cell (CTC) count associated with the response to neoadjuvant chemotherapy in local advanced breast cancer? A meta-analysis. Oncol Res Treat 2014; 37(5): 250-4.
[23]
Yan WT, Cui X, Chen Q, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: A meta-analysis. Sci Rep 2017; 7: 43464.
[24]
Molloy TJ, Devriese LA, Helgason HH, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer 2011; 104(12): 1913-9.
[25]
Hartkopf AD, Wallwiener M, Hahn M, Fehm TN, Brucker SY, Taran FA. Simultaneous detection of disseminated and circulating tumor cells in primary breast cancer patients. Cancer Res Treat 2016; 48(1): 115-24.
[26]
Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 2012; 13(7): 688-95.
[27]
Karhade M, Hall C, Mishra P, et al. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat 2014; 147(2): 325-33.
[28]
Rack B, Schindlbeck C, Juckstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106(5): dju066.
[29]
Hall CS, Karhade MG, Bowman Bauldry JB, et al. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg 2016; 223(1): 20-9.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 6
Year: 2019
Page: [519 - 529]
Pages: 11
DOI: 10.2174/1574888X14666190306103759
Price: $58

Article Metrics

PDF: 38
HTML: 1